A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Trial Identifier: D5339C00001
Sponsor: AstraZeneca
NCTID:: NCT04564027
Start Date: December 2020
Primary Completion Date: April 2023
Study Completion Date: February 2025
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish Translation
French Translation

Trial Locations

Country Location
ES Barcelona, ES, 08036
ES Barcelona, ES, 8035
ES Barcelona, ES, 08907
ES Cáceres, ES, 10003
ES Madrid, ES, 28050
ES Madrid, ES, 28041
ES Madrid, ES, 28034
FR Bordeaux, FR, 33076
FR Dijon, FR, 21079
FR Lyon, FR, 69373
FR Poitiers Cedex, FR, 86021
FR Vandoeuvre les Nancy, FR, 54519
US, AZ Tucson, AZ, US, 85719
US, CA Beverly Hills, CA, US, 90211
US, CA Duarte, CA, US, 91010
US, CA La Jolla, CA, US, 92093
US, CA Los Angeles, CA, US, 90089
US, CA Sacramento, CA, US, 95817
US, CA San Francisco, CA, US, 94115
US, FL Tampa, FL, US, 33612
US, IN Indianapolis, IN, US, 46202
US, LA New Orleans, LA, US, 70056
US, MA Boston, MA, US, 02215
US, MD Baltimore, MD, US, 21231
US, MI Ann Arbor, MI, US, 48109
US, MN Saint Paul, MN, US, 55102
US, NV Las Vegas, NV, US, 89119
US, NY New York, NY, US, 10065
US, NY Syracuse, NY, US, 13210
US, PA Ephrata, PA, US, 17522
US, PA Philadelphia, PA, US, 19104
US, SC Myrtle Beach, SC, US, 29572